Neuronal nicotinic acetylcholine receptor alpha-4 beta-2 subtype (α4β2 nAChR)

The neuronal nicotinic acetylcholine receptor alpha-4 beta-2 (α4β2) subtype is a pentameric ligand-gated ion channel predominantly expressed in the mammalian central nervous system (UniProt P43681, P17677). It represents the most abundant high-affinity nicotinic receptor in the brain and plays a critical role in mediating the reinforcing effects of nicotine by modulating the release of neurotransmitters such as dopamine, GABA, and glutamate (PMID: 17030501). Beyond its role in addiction, the α4β2 receptor is involved in cognitive functions including attention, learning, and memory (StatPearls NBK531483). Dysregulation or genetic mutations in the subunits of this receptor are linked to various neurological conditions, including autosomal dominant nocturnal frontal lobe epilepsy and cognitive decline in Alzheimer's disease (PMID: 21840305). Pharmacological targeting of α4β2 receptors is a primary strategy for smoking cessation, where partial agonists like varenicline are used to alleviate withdrawal while preventing nicotine-induced reward (PubChem CID 170311). Additionally, research continues into its potential as a target for treating neurodegenerative diseases, pain, and mood disorders.

Other names

alpha4beta2 nicotinic receptorCHRNA4-CHRNB2 receptorNeuronal acetylcholine receptor alpha-4 beta-2High-affinity nicotinic receptor

Partial agonism, full agonism, or antagonism of the pentameric ion channel to modulate the influx of cations (Na+, K+, Ca2+), thereby regulating neuronal excitability and the release of neurotransmitters like dopamine and glutamate (PMID: 17030501).